Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine.
Simeon, Vittorio; Todoerti, Katia; La Rocca, Francesco; Caivano, Antonella; Trino, Stefania; Lionetti, Marta; Agnelli, Luca; De Luca, Luciana; Laurenzana, Ilaria; Neri, Antonino; Musto, Pellegrino.
Int J Mol Sci
; 16(8): 17514-34, 2015 Jul 30.
Artigo em Inglês | MEDLINE | ID: mdl-26263974
Thirty patients with primary plasma cell leukemia: a single center experience.
Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14).
Chromosome abnormalities defined by conventional cytogenetics in plasma cell leukemia: what have we learned about its biology?
Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).
Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
[Plasma cell leukemia induced to complete remission with negative minimal residual disease by qualitative PCR analysis after hyper-CVAD and high-dose melphalan followed by autologous peripheral blood stem cell transplantation].
Complex rearrangements involving der(8)t(8;20) and der(14)t(8;14)t(11;14), CCND1, and duplication of IgH constant region in acute plasmablastic leukemia.
Plasma cell leukemia with an unusual karyotype and prolonged survival following oral alkylating agent therapy.
Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation.